Clinical Trial Update: Sunitinib in Treating Patients With Relapsed or Refractory Diffuse or Mediastinal Large B-Cell Lymphoma [Phase 2]

View source ↗

Summary

This Phase 2 trial assessed the use of sunitinib in adults with relapsed or refractory diffuse large B-cell lymphoma, including mediastinal large B-cell lymphom…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Mediastinal Large B-cell Lymphoma

Drugs mentioned

• Sutent (sunitinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2013-12-12